These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 25724854)

  • 41. Activity of oritavancin against methicillin-resistant staphylococci, vancomycin-resistant enterococci and β-haemolytic streptococci collected from western European countries in 2011.
    Morrissey I; Seifert H; Canton R; Nordmann P; Stefani S; Macgowan A; Janes R; Knight D;
    J Antimicrob Chemother; 2013 Jan; 68(1):164-7. PubMed ID: 22941898
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Worldwide assessment of dalbavancin activity and spectrum against over 6,000 clinical isolates.
    Streit JM; Fritsche TR; Sader HS; Jones RN
    Diagn Microbiol Infect Dis; 2004 Feb; 48(2):137-43. PubMed ID: 14972384
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Clinical relevance of a European collaborative study on comparative susceptibility of gram-positive clinical isolates to teicoplanin and vancomycin.
    Grüneberg RN; Hryniewicz W
    Int J Antimicrob Agents; 1998 Nov; 10(4):271-7. PubMed ID: 9916900
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Telavancin: mechanisms of action, in vitro activity, and mechanisms of resistance.
    Karlowsky JA; Nichol K; Zhanel GG
    Clin Infect Dis; 2015 Sep; 61 Suppl 2():S58-68. PubMed ID: 26316559
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Update on the in vitro activity of dalbavancin against indicated species (Staphylococcus aureus, Enterococcus faecalis, β-hemolytic streptococci, and Streptococcus anginosus group) collected from United States hospitals in 2017-2019.
    Sader HS; Streit JM; Mendes RE
    Diagn Microbiol Infect Dis; 2021 Jan; 99(1):115195. PubMed ID: 32977116
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [In vitro activity of vancomycin and teicoplanin against gram-positive cocci].
    Bezian MC; Ribou G; Masquelier B
    Pathol Biol (Paris); 1992 May; 40(5):461-5. PubMed ID: 1386667
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Drug susceptibility testing of clinical isolates of streptococci and enterococci by the Phoenix automated microbiology system.
    Brigante GR; Luzzaro FA; Pini B; Lombardi G; Sokeng G; Toniolo AQ
    BMC Microbiol; 2007 May; 7():46. PubMed ID: 17521437
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Update of the telavancin activity in vitro tested against a worldwide collection of Gram-positive clinical isolates (2013), when applying the revised susceptibility testing method.
    Mendes RE; Farrell DJ; Sader HS; Streit JM; Jones RN
    Diagn Microbiol Infect Dis; 2015 Apr; 81(4):275-9. PubMed ID: 25618421
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Activity of dalbavancin against staphylococci and streptococci, assessed by BSAC and NCCLS agar dilution methods.
    Mushtaq S; Warner M; Johnson AP; Livermore DM
    J Antimicrob Chemother; 2004 Sep; 54(3):617-20. PubMed ID: 15321983
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Activity of oritavancin against Gram-positive clinical isolates responsible for documented skin and soft-tissue infections in European and US hospitals (2010-13).
    Mendes RE; Farrell DJ; Sader HS; Flamm RK; Jones RN
    J Antimicrob Chemother; 2015 Feb; 70(2):498-504. PubMed ID: 25362568
    [TBL] [Abstract][Full Text] [Related]  

  • 51.
    Plota M; Papadimitriou-Olivgeris M; Kolonitsiou F; Tsiata E; Spiliopoulou I; Assimakopoulos SF; Marangos M
    J Med Microbiol; 2021 Sep; 70(9):. PubMed ID: 34559042
    [No Abstract]   [Full Text] [Related]  

  • 52. Update on activity of dalbavancin and comparators against clinical isolates of Gram-positive pathogens from Europe and Russia (2017-2018), and on clonal distribution of MRSA.
    Riccobono E; Giani T; Baldi G; Arcangeli S; Antonelli A; Tellone V; Del Vecchio A; De Joannon AC; Rossolini GM
    Int J Antimicrob Agents; 2022 Feb; 59(2):106503. PubMed ID: 34929289
    [TBL] [Abstract][Full Text] [Related]  

  • 53. An international activity and spectrum analysis of linezolid: ZAAPS Program results for 2011.
    Flamm RK; Mendes RE; Ross JE; Sader HS; Jones RN
    Diagn Microbiol Infect Dis; 2013 Jun; 76(2):206-13. PubMed ID: 23478031
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Antimicrobial susceptibility of gram-positive bacteria isolated from European medical centres: results of the Daptomycin Surveillance Programme (2002-2004).
    Sader HS; Streit JM; Fritsche TR; Jones RN
    Clin Microbiol Infect; 2006 Sep; 12(9):844-52. PubMed ID: 16882289
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Dalbavancin Activity When Tested against Streptococcus pneumoniae Isolated in Medical Centers on Six Continents (2011 to 2014).
    Jones RN; Schuchert JE; Mendes RE
    Antimicrob Agents Chemother; 2016 Jun; 60(6):3419-25. PubMed ID: 27001811
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Antimicrobial activity of the investigational pleuromutilin compound BC-3781 tested against Gram-positive organisms commonly associated with acute bacterial skin and skin structure infections.
    Sader HS; Biedenbach DJ; Paukner S; Ivezic-Schoenfeld Z; Jones RN
    Antimicrob Agents Chemother; 2012 Mar; 56(3):1619-23. PubMed ID: 22232289
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Study of the susceptibility of Staphylococcus sp. and Enterococcus sp. to teicoplanin and vancomycin].
    Mimica I; Mendes CM; Mimica L; Oplustil C; Pignatari AC; Sader H
    Rev Assoc Med Bras (1992); 1996; 42(3):147-50. PubMed ID: 9138356
    [TBL] [Abstract][Full Text] [Related]  

  • 58. In vitro activity of nemonoxacin (TG-873870), a novel non-fluorinated quinolone, against clinical isolates of Staphylococcus aureus, enterococci and Streptococcus pneumoniae with various resistance phenotypes in Taiwan.
    Chen YH; Liu CY; Lu JJ; King CH; Hsueh PR
    J Antimicrob Chemother; 2009 Dec; 64(6):1226-9. PubMed ID: 19833635
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Evaluation of the VITEK 2 system for identification and antimicrobial susceptibility testing of medically relevant gram-positive cocci.
    Ligozzi M; Bernini C; Bonora MG; De Fatima M; Zuliani J; Fontana R
    J Clin Microbiol; 2002 May; 40(5):1681-6. PubMed ID: 11980942
    [TBL] [Abstract][Full Text] [Related]  

  • 60. In vitro activity of telavancin against gram-positive clinical isolates recently obtained in Europe.
    Jansen WT; Verel A; Verhoef J; Milatovic D
    Antimicrob Agents Chemother; 2007 Sep; 51(9):3420-4. PubMed ID: 17606689
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.